Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers. This content was developed independently ...

Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion.Austin, United States, March 19, 2026 (GLOBE NEWSWIRE) -- ...

Cabaletta Bio (NASDAQ:CABA) used a fireside chat at TD Cowen’s 46th Annual Health Care Conference to highlight progress ...

Localized Scleroderma (LoS), particularly aggressive subtypes such as Deep Morphea (morphea profunda), is a rare chronic autoimmune fibrosing disorder that can extend into the subcutaneous tissue, ...

Normally, your immune system fights off disease and protects your body from infection. However, when you have an autoimmune disease, your immune system mistakenly attacks healthy cells, tissues and ...

Juvenile localized scleroderma (JLS) is a rare, potentially disabling inflammatory skin disease, and there are currently no US Food and Drug Administration approved therapies for this population.

Researchers conducted a retrospective cohort study of 114 patients (68% female; median age at onset, 8.3 years; 92% White) with juvenile localized scleroderma from the National Registry for Childhood ...

Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

BOSTON, Jan. 23, 2026 /PRNewswire/ -- Privo Technologies, Inc., ("Privo") today announced that enrollment has been completed for Arm 2 of the CLN-004 clinical trial evaluating PRV211, and that the ...

Introduction The majority of all patients with systemic sclerosis (SSc) experience hand function impairment. The exact cause for this impairment is yet unknown. As impaired hand function hugely ...